Xvivo Perfusion Ab Stock Market Value
| XVIPF Stock | USD 26.75 1.98 7.99% |
| Symbol | Xvivo |
Xvivo Perfusion 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xvivo Perfusion's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xvivo Perfusion.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Xvivo Perfusion on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Xvivo Perfusion AB or generate 0.0% return on investment in Xvivo Perfusion over 90 days. Xvivo Perfusion is related to or competes with PolyNovo, 4DMedical, CellaVision, Swedencare, Viva Biotech, Beijing Tong, and Sosei Group. Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfu... More
Xvivo Perfusion Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xvivo Perfusion's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xvivo Perfusion AB upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.67 | |||
| Information Ratio | 0.2222 | |||
| Maximum Drawdown | 18.41 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 7.99 |
Xvivo Perfusion Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xvivo Perfusion's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xvivo Perfusion's standard deviation. In reality, there are many statistical measures that can use Xvivo Perfusion historical prices to predict the future Xvivo Perfusion's volatility.| Risk Adjusted Performance | 0.1784 | |||
| Jensen Alpha | 0.7433 | |||
| Total Risk Alpha | 0.6056 | |||
| Sortino Ratio | 0.1986 | |||
| Treynor Ratio | 1.28 |
Xvivo Perfusion February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1784 | |||
| Market Risk Adjusted Performance | 1.29 | |||
| Mean Deviation | 1.87 | |||
| Semi Deviation | 0.6946 | |||
| Downside Deviation | 3.67 | |||
| Coefficient Of Variation | 423.86 | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.77 | |||
| Information Ratio | 0.2222 | |||
| Jensen Alpha | 0.7433 | |||
| Total Risk Alpha | 0.6056 | |||
| Sortino Ratio | 0.1986 | |||
| Treynor Ratio | 1.28 | |||
| Maximum Drawdown | 18.41 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 7.99 | |||
| Downside Variance | 13.47 | |||
| Semi Variance | 0.4824 | |||
| Expected Short fall | (7.33) | |||
| Skewness | 2.45 | |||
| Kurtosis | 7.21 |
Xvivo Perfusion AB Backtested Returns
Xvivo Perfusion appears to be not too volatile, given 3 months investment horizon. Xvivo Perfusion AB shows Sharpe Ratio of 0.24, which attests that the company had a 0.24 % return per unit of risk over the last 3 months. By examining Xvivo Perfusion's technical indicators, you can evaluate if the expected return of 0.77% is justified by implied risk. Please utilize Xvivo Perfusion's Mean Deviation of 1.87, downside deviation of 3.67, and Market Risk Adjusted Performance of 1.29 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Xvivo Perfusion holds a performance score of 18. The firm maintains a market beta of 0.6, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xvivo Perfusion's returns are expected to increase less than the market. However, during the bear market, the loss of holding Xvivo Perfusion is expected to be smaller as well. Please check Xvivo Perfusion's treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Xvivo Perfusion's historical returns will revert.
Auto-correlation | 0.61 |
Good predictability
Xvivo Perfusion AB has good predictability. Overlapping area represents the amount of predictability between Xvivo Perfusion time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xvivo Perfusion AB price movement. The serial correlation of 0.61 indicates that roughly 61.0% of current Xvivo Perfusion price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.61 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 4.43 |
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.